These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 4271633)

  • 1. [Human platelet antiplasmin. Detection and determination of a noncompetitive inhibitor effect of plasmin using a technic with radiofibrinogen].
    Dechavanne M; Lagarde M; Thouverez JP; Viala JJ
    Pathol Biol (Paris); 1973 Nov; 21():Suppl:31-5. PubMed ID: 4271633
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetics of the inhibition of plasmin in acidified human plasma.
    Lijnen HR; Maes M; Castel M; Samama M; Collen D
    Thromb Haemost; 1982 Dec; 48(3):257-9. PubMed ID: 6219470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen interaction with platelets: the importance of carboxyterminal lysines.
    Horne MK; Merryman PK; Cullinane AM
    Thromb Res; 2005; 116(6):499-507. PubMed ID: 15894352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemical characterization of the plasmin-antiplasmin system. Basis for the specific detection of the plasmin-antiplasmin complex by latex agglutination assays.
    Plow EF; de Cock F; Collen D
    J Lab Clin Med; 1979 Feb; 93(2):199-209. PubMed ID: 85679
    [No Abstract]   [Full Text] [Related]  

  • 6. Exposure of human platelets to plasmin results in the expression of irreversibly active fibrinogen receptors.
    Rabhi-Sabile S; Pidard D
    Thromb Haemost; 1995 Apr; 73(4):693-701. PubMed ID: 7495081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrastructural studies on the binding sites of fibrinogen on platelet surface during aggregation.
    Morgenstern E; Reimers HJ; Miyashita C
    Acta Histochem Suppl; 1984; 29():183-9. PubMed ID: 6232644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some properties of an antiplasmin substance from rabbit platelets.
    Wakabayashi K; Fujikawa K; Abe T
    Thromb Diath Haemorrh; 1970 Oct; 24(1):76-84. PubMed ID: 4249469
    [No Abstract]   [Full Text] [Related]  

  • 10. Pretreatment of human platelets with plasmin inhibits responses to thrombin, but potentiates responses to low concentrations of aggregating agents, including the thrombin receptor activating peptide, SFLLRN.
    Kinlough-Rathbone RL; Perry DW; Rand ML; Packham MA
    Thromb Haemost; 1997 Apr; 77(4):741-7. PubMed ID: 9134653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmatic and platelet anti-plasmins and anti-activators. 3. Results in normal people, in patients and in those with venous thrombosis.
    den Ottolander GJ; Leijnse B; Cremer-Elfrink HM
    Thromb Diath Haemorrh; 1969 Feb; 21(1):35-41. PubMed ID: 4237624
    [No Abstract]   [Full Text] [Related]  

  • 12. I. Studies on the determination of fibrinogen in human blood plasma. II. Studies on the trypsin and plasmin inhibitors in human blood serum.
    JACOBSSON K
    Scand J Clin Lab Invest; 1955; 7 Suppl. 14():3-102. PubMed ID: 14372894
    [No Abstract]   [Full Text] [Related]  

  • 13. Isolation and properties of a low molecular weight antiplasmin of human blood platelets and serum.
    Mui PT; James HL; Ganguly P
    Br J Haematol; 1975 Apr; 29(4):627-37. PubMed ID: 127607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new method for antiplasmin activity determination.
    Wolosowicz N; Prokopowicz J
    Haematologia (Budap); 1971; 5(3):293-9. PubMed ID: 4256875
    [No Abstract]   [Full Text] [Related]  

  • 15. On the mechanism of plasmin-induced aggregation of human platelets: implication of secreted von Willebrand factor.
    Rabhi-Sabile S; de Romeuf C; Pidard D
    Thromb Haemost; 1998 Jun; 79(6):1191-8. PubMed ID: 9657447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of blood serum antiplasmin and euglobulins on fibrinolysis and fibrinogenolysis in vitro].
    Bratus' GM; Gorodetskiĭ AL; Byshevskiĭ ASh
    Vopr Med Khim; 1971; 17(5):547-9. PubMed ID: 4256467
    [No Abstract]   [Full Text] [Related]  

  • 17. Blood inhibitory capacity toward exogenous plasmin.
    Banbula A; Zimmerman TP; Novokhatny VV
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):241-6. PubMed ID: 17413760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of plasmin-induced platelet aggregation.
    Watabe A; Ohta M; Matsuyama N; Mizuno K; el Borai N; Tanimoto T; Kawanishi T; Hayakawa T
    Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):341-52. PubMed ID: 9261893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Have the platelet antiheparin and antiplasmin activities the same support?
    Moriau M
    Thromb Diath Haemorrh; 1969 Nov; 22(2):403-7. PubMed ID: 4245336
    [No Abstract]   [Full Text] [Related]  

  • 20. Nonadrenergic imidazoline binding sites on human platelets.
    Piletz JE; Sletten K
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1493-502. PubMed ID: 8263811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.